Quantbot Technologies LP Increases Position in RxSight, Inc. $RXST

Quantbot Technologies LP raised its stake in shares of RxSight, Inc. (NASDAQ:RXST) by 168.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 146,248 shares of the company’s stock after purchasing an additional 91,815 shares during the period. Quantbot Technologies LP’s holdings in RxSight were worth $1,315,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in RXST. Raymond James Financial Inc. purchased a new position in RxSight in the 2nd quarter worth approximately $28,000. Bessemer Group Inc. purchased a new position in shares of RxSight during the 2nd quarter worth $33,000. Tower Research Capital LLC TRC increased its position in shares of RxSight by 156.2% during the second quarter. Tower Research Capital LLC TRC now owns 5,574 shares of the company’s stock valued at $72,000 after acquiring an additional 3,398 shares during the last quarter. Russell Investments Group Ltd. increased its holdings in RxSight by 112.3% in the 2nd quarter. Russell Investments Group Ltd. now owns 8,684 shares of the company’s stock valued at $113,000 after purchasing an additional 4,593 shares during the last quarter. Finally, Osaic Holdings Inc. raised its holdings in shares of RxSight by 1,417.0% in the 2nd quarter. Osaic Holdings Inc. now owns 9,572 shares of the company’s stock valued at $124,000 after buying an additional 8,941 shares during the period. Hedge funds and other institutional investors own 78.78% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on RXST shares. Piper Sandler reduced their price objective on RxSight from $11.00 to $10.00 and set a “neutral” rating on the stock in a research note on Thursday, February 26th. William Blair assumed coverage on shares of RxSight in a report on Friday, January 30th. They set a “market perform” rating on the stock. UBS Group boosted their target price on RxSight from $8.00 to $9.00 and gave the company a “neutral” rating in a report on Thursday, February 26th. Stifel Nicolaus set a $10.00 price target on shares of RxSight in a research report on Thursday, November 6th. Finally, Morgan Stanley increased their price objective on RxSight from $9.00 to $10.00 and gave the stock an “equal weight” rating in a research report on Tuesday, December 2nd. Two research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Reduce” and an average target price of $9.89.

RxSight Stock Performance

Shares of NASDAQ:RXST opened at $7.81 on Friday. The stock has a market cap of $322.32 million, a PE ratio of -8.22 and a beta of 1.16. The business’s fifty day moving average price is $9.06 and its two-hundred day moving average price is $9.48. RxSight, Inc. has a one year low of $6.32 and a one year high of $27.13.

About RxSight

RxSight, Inc is a medical technology company focused on the development and commercialization of advanced intraocular lens (IOL) systems for patients undergoing cataract surgery and lens replacement procedures. The company’s flagship product, the Light Adjustable Lens (LAL), is designed to provide customized vision correction by allowing non‐invasive post‐operative adjustments. Using ultraviolet light, surgeons can fine‐tune the lens power after implantation to achieve optimal visual outcomes, reducing reliance on glasses or contact lenses and enhancing patient satisfaction.

Founded in 2011 and headquartered in Aliso Viejo, California, RxSight has pursued regulatory clearances and market access across multiple regions.